Summary
Global Markets Direct’s, ‘Compugen Ltd. - Product Pipeline Review - 2016’, provides an overview of the Compugen Ltd.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Compugen Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Compugen Ltd.
- The report provides overview of Compugen Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Compugen Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Compugen Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Compugen Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Compugen Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Compugen Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Compugen Ltd. Snapshot 6
Compugen Ltd. Overview 6
Key Information 6
Key Facts 6
Compugen Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Compugen Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Compugen Ltd. - Pipeline Products Glance 14
Compugen Ltd. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Compugen Ltd. - Drug Profiles 16
CGEN-15001 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CGEN-15021 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CGEN-15031 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CGEN-15051 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CGEN-15091 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CGEN-25009 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CGEN-856S 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody to Inhibit CGEN-15049 for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody to Inhibit CGEN-15052 for Oncology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Inhibit CGEN-15092 for Multiple Sclerosis 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody 1 to Inhibit CGEN-15029 for Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody 2 to Target B7/CD28 for Oncology 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody 3 to Target B7/CD28 for Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody 4 to Target B7/CD28 for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclonal Antibody 5 to Target B7/CD28 for Oncology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody Conjugate 2 for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody Conjugates 1 for Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody for Cancer 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody to Inhibit CGEN-15027 for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody to Target CGEN-928 for Multiple Myeloma 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Compugen Ltd. - Pipeline Analysis 38
Compugen Ltd. - Pipeline Products by Target 38
Compugen Ltd. - Pipeline Products by Molecule Type 39
Compugen Ltd. - Pipeline Products by Mechanism of Action 40
Compugen Ltd. - Recent Pipeline Updates 41
Compugen Ltd. - Dormant Projects 45
Compugen Ltd. - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Compugen Ltd., Key Information 6
Compugen Ltd., Key Facts 6
Compugen Ltd. - Pipeline by Indication, 2016 8
Compugen Ltd. - Pipeline by Stage of Development, 2016 10
Compugen Ltd. - Monotherapy Products in Pipeline, 2016 11
Compugen Ltd. - Out-Licensed Products in Pipeline, 2016 12
Compugen Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Compugen Ltd. - Preclinical, 2016 14
Compugen Ltd. - Discovery, 2016 15
Compugen Ltd. - Pipeline by Target, 2016 38
Compugen Ltd. - Pipeline by Molecule Type, 2016 39
Compugen Ltd. - Pipeline Products by Mechanism of Action, 2016 40
Compugen Ltd. - Recent Pipeline Updates, 2016 41
Compugen Ltd. - Dormant Developmental Projects,2016 45
Compugen Ltd., Subsidiaries 46
List of Figures
Compugen Ltd. - Pipeline by Indication, 2016 8
Compugen Ltd. - Pipeline by Stage of Development, 2016 10
Compugen Ltd. - Monotherapy Products in Pipeline, 2016 11
Compugen Ltd. - Pipeline by Target, 2016 38
Compugen Ltd. - Pipeline by Molecule Type, 2016 39
Compugen Ltd. - Pipeline Products by Mechanism of Action, 2016 40
